Actively Recruiting
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Led by University of Zurich · Updated on 2024-05-08
600
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
Sponsors
U
University of Zurich
Lead Sponsor
S
Swiss HIV Cohort Study
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.
CONDITIONS
Official Title
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant in the Swiss HIV Cohort Study
- All participants initiating the cabotegravir plus rilpivirine long-acting regimen
- All participants on standard of care oral regimen
You will not qualify if you...
- Not participating in the Swiss HIV Cohort Study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Zurich
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
D
Dominique L Braun, MD
CONTACT
J
Jessy J Duran Ramirez, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here